REGENXBIO Prices Public Offering Of 3.70 Mln Shares At $20.50/Shr

(RTTNews) - REGENXBIO Inc. (RGNX) announced the pricing of an underwritten public offering of 3.70 million shares of its common stock at $20.50 per share. This offering is expected to close on March 27, 2017.

The company expects gross proceeds from this offering to be approximately $75.85 million and has granted the underwriters a 30-day option to buy an additional 555,000 shares of common stock.

In February 2017, REGENXBIO announced the IND application for RGX-314 for the treatment of wet age-related macular degeneration is active. The company said it is on track to begin enrollment in the RGX-314 Phase I clinical trial by mid-2017, and to provide an interim trial update by the end of 2017.

In March 2017, the company began dosing for the Phase I/II clinical trial evaluating RGX-501 for the treatment of homozygous familial hypercholesterolemia (HoFH). The company will provide an interim trial update from the RGX-501 clinical trial in late 2017.

REGENXBIO plans to file an IND for the Phase I/II clinical trial of RGX-111 for the treatment of Mucopolysaccharidosis Type I (MPS I) in the first half of 2017.

REGENXBIO plans to file an IND for RGX-121 for the treatment of Mucopolysaccharidosis Type II (MPS II) in mid-2017.